TM6SF2 and metabolic dysfunction-associated steatotic liver disease: A 2024 metabolomic study is the first to systematically compare differences in VLDL secretion and disease progression in three subtypes of MASLD; the PNPLA3 variant does not affect hepatic VLDL secretion, which is more common in metabotypes associated with CVD, whereas the transmembrane 6 superfamily member 2 (TM6SF2) variant is associated with reduced VLDL secretion [22].